Agios Pharmaceuticals (NASDAQ:AGIO) Stock Rating Reaffirmed by Cantor Fitzgerald

Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a research report issued on Friday, Benzinga reports.

AGIO has been the topic of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. The Goldman Sachs Group lifted their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research note on Tuesday, June 4th. Finally, StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $51.33.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock traded up $0.09 during trading on Friday, hitting $47.47. The stock had a trading volume of 133,865 shares, compared to its average volume of 704,262. The business has a fifty day moving average of $45.69 and a two-hundred day moving average of $39.03. Agios Pharmaceuticals has a fifty-two week low of $19.80 and a fifty-two week high of $50.35. The firm has a market cap of $2.70 billion, a P/E ratio of -7.50 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.51) EPS. As a group, research analysts forecast that Agios Pharmaceuticals will post -4.85 earnings per share for the current year.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $37,000. Quest Partners LLC bought a new position in Agios Pharmaceuticals during the second quarter valued at about $40,000. NEOS Investment Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $210,000. North Star Asset Management Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $216,000. Finally, XTX Topco Ltd bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $230,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.